Trials / Completed
CompletedNCT00624026
Memantine - Communication Study
Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine-HCl | 20 mg per day (once daily) |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-02-26
- Last updated
- 2011-11-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00624026. Inclusion in this directory is not an endorsement.